FXYD domain containing ion transport regulator 6Genealiases: []
Q-omics provides the consensus-scored FXYD6 profile across patient tissues and cancer cell-line models. FXYD6 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, FXYD6 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, FXYD6 RNA expression shows 23,389 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, and GBM as cancer lineages where FXYD6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FXYD6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FXYD6 survival associations across molecular data types. FXYD6 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FXYD6 RNA expression–survival associations across cancer types. High FXYD6 expression shows unfavorable associations in BLCA and MESO, but favorable associations in KIRC, UCS, LGG and PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for FXYD6 RNA expression.
This table summarizes FXYD6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FXYD6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FXYD6 shows lower tumor expression in BLCA, KIRP, KIRC, LUAD, COAD and THCA. The BLCA box plot shows higher FXYD6 RNA expression in normal versus tumor tissue (log2 FC = −5.002, t-test p < 0.001).
This table shows molecular features associated with FXYD6 in patient tissues and cancer cell lines. In patient samples, FXYD6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FXYD6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and OESOPHAGUS.
